Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge

Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · see citing works

Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association

Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333 · see citing works

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works

Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641 · see citing works

Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association

Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208 · see citing works

Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials

Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · see citing works

A comprehensive evaluation of the heparin–manganese precipitation procedure for estimating high density lipoprotein cholesterol

Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250 · see citing works

Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy

Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 735 · see citing works

Diagnosing Insulin Resistance by Simple Quantitative Methods in Subjects With Normal Glucose Metabolism

Ascaso, J. F., Pardo, S., Real, J. T., Lorente, R. I., Priego, A., & Carmena, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3320 · Cited by 490 · see citing works

Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users

Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486 · see citing works

The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: An Approach to Accurate and Precise Lipid Measurements

Myers, G. L., Cooper, G. R., Winn, C., & Smith, S. J. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30645-0 · Cited by 404 · see citing works

De novo lipogenesis in humans: metabolic and regulatory aspects

Hellerstein, M. (1999) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600744 · Cited by 246 · see citing works

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Pinkosky, S. L., Filippov, S. I., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 240 · see citing works

Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial

Insull, W., Toth, P. D., Mullican, W. S., Hunninghake, D. B., Burke, S. K., Donovan, J. M., & Davidson, M. H. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.10.971 · Cited by 138 · see citing works

EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EZETIMIBE IN PRIMARY HYPERCHOLESTEROLAEMIA: A POOLED ANALYSIS FROM TWO CONTROLLED PHASE III CLINICAL STUDIES

Knopp, R., Dujovne, C. A., LeBeaut, A., Lipka, L., Suresh, R., & Veltri, E. P. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10508.x · Cited by 133 · see citing works

Weighing the benefits of high-dose simvastatin against the risk of myopathy

Egan, A., & Colman, E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1106689 · Cited by 113 · see citing works

Clinical trial experience with extended-release niacin (niaspan): dose-escalation study

Goldberg, A. C. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00952-7 · Cited by 95 · see citing works

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

Cramer, C. T., Goetz, B. D., Hopson, K. L., Fici, G. J., Ackermann, R., Brown, S. C., Bisgaier, C. L., Rajeswaran, W. G., Oniciu, D. C., & Pape, M. E. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400018-jlr200 · Cited by 74 · see citing works

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia

Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90871-0 · Cited by 65 · cited 2× · see citing works

Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease

Virani, S. S., Woodard, L., Chitwood, S. S., Landrum, C. R., Urech, T. H., Wang, D., Murawsky, J., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.013 · Cited by 56 · see citing works

Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.

Dierkes, J., Luley, C. H., & Westphal, S. (2007) · PubMed Central · Cited by 43 · see citing works

The College of American Pathologists laboratory accreditation program

Rabinovitch, A. (2002) · Accreditation and Quality Assurance · doi:10.1007/s00769-002-0537-0 · Cited by 36 · see citing works

What the Statin Trials Have Taught Us

Waters, D. D. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.066 · Cited by 35 · see citing works

Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction

Martin, S. S., GOSCH, K. L., Kulkarni, K. R., Spertus, J. A., Mathews, R., Ho, P. M., Maddox, T. M., Newby, L. K., Alexander, K. P., & Wang, T. Y. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.10.005 · Cited by 31 · see citing works

Nabumetone in the treatment of active adult rheumatoid arthritis

Brobyn, R. D. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90594-8 · Cited by 12 · see citing works

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988 · see citing works

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · see citing works

Metabolic reprogramming and epigenetic modifications on the path to cancer

Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 796 · see citing works

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498 · see citing works

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432 · see citing works

Metabolic reprogramming in liver fibrosis

Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432 · see citing works

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422 · see citing works

Metabolic control of epigenetics in cancer

Kinnaird, A. S., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.82 · Cited by 419 · see citing works

ATP-citrate lyase controls a glucose-to-acetate metabolic switch

Zhao, S., Torres, A., Henry, R. A., Trefely, S., Wallace, M., Lee, J. V., Carrer, A., Sengupta, A., Campbell, S. L., Kuo, Y.-M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.069 · Cited by 394 · see citing works

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D., Oliver‐Williams, C., Wood, A., Butterworth, A. S., Angelantonio, E. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 340 · see citing works

LDL cholesterol: controversies and future therapeutic directions

Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274 · see citing works

Lipid management in patients with chronic kidney disease

Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works

ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review

Feng, X., Zhang, L., Xu, S., & Shen, A.-Z. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.101006 · Cited by 233 · see citing works

Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol

Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · see citing works

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171 · see citing works

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170 · see citing works

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance

Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 158 · see citing works

Hyperlipidemia and cardiovascular disease

Tietge, U. J. F. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000051 · Cited by 146 · see citing works

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Thompson, P. D., MacDougall, D. E., Newton, R. S., Margulies, J. R., Hanselman, J. C., Orloff, D. G., McKenney, J. M., & Ballantyne, C. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.025 · Cited by 142 · see citing works

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136 · see citing works

National lipid association annual summary of clinical lipidology 2016

Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128 · see citing works

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

Bilen, O., & Ballantyne, C. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0611-4 · Cited by 119 · see citing works

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

Ballantyne, C. M., McKenney, J. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.043 · Cited by 117 · see citing works

Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders

Pinkosky, S. L., Groot, P. H. E., Lalwani, N. D., & Steinberg, G. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.001 · Cited by 117 · see citing works

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

Cicero, A. F. G., Fogacci, F., Hernández, A. V., & Banach, M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003121 · Cited by 107 · see citing works

Bempedoic Acid: First Approval

Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01308-w · Cited by 99 · see citing works

Is AMPK the savior of the failing heart?

Kim, T. T., & Dyck, J. R. B. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.001 · Cited by 97 · see citing works

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr −/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid

Samsoondar, J. P., Burke, A. C., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Pinkosky, S. L., Newton, R. S., & Huff, M. W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308963 · Cited by 96 · see citing works

ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia

Burke, A. C., & Huff, M. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000390 · Cited by 91 · see citing works

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 84 · see citing works

National Lipid Association Annual Summary of Clinical Lipidology 2015

Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 81 · see citing works

Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)

Banach, M., Penson, P. E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.03.001 · Cited by 77 · see citing works

New Therapeutic Approaches to the Treatment of Dyslipidemia

Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 73 · see citing works

Current and future trends in the lipid lowering therapy

Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 69 · see citing works

Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis

Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 67 · see citing works

AMP-activated protein kinase sparks the fire of cardioprotection against myocardial ischemia and cardiac ageing

Gu, C., Li, T. X., Jiang, S., Yang, Z. P., Lv, J., Yi, W., Yang, Y., & Fang, M. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.08.002 · Cited by 66 · see citing works

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65 · see citing works

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Minno, A. D., Lupoli, R., Calcaterra, I. L., Poggio, P., Forte, F., Spadarella, G., Ambrosino, P., Iannuzzo, G., & Minno, M. N. D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016262 · Cited by 67 · see citing works

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From <i>ATVB</i> Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · see citing works

Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Wang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01101-9 · Cited by 60 · see citing works

New Era of Lipid-Lowering Drugs

Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59 · see citing works

Lipids, blood pressure and kidney update 2015

Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57 · see citing works

Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol

Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56 · see citing works

ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

Ruscica, M., Banach, M., Sahebkar, A., Corsini, A., & Sirtori, C. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583209 · Cited by 55 · see citing works

Bempedoic Acid (ETC-1002)

Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51 · see citing works

New Trends in Dyslipidemia Treatment

Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 56 · see citing works

Contemporary Management of Dyslipidemia

Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 56 · see citing works

Evaluating bempedoic acid for the treatment of hyperlipidaemia

Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 52 · see citing works

Adipose-Derived Mesenchymal Stem Cells Ameliorate Lipid Metabolic Disturbance in Mice

Liu, G.-Y., Liu, J., Wang, Y., Liu, Y., Shao, Y., Han, Y., Qin, Y.-R., Xiao, F., Li, P., Zhao, L., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0239 · Cited by 52 · see citing works

Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia

Lemus, H. N., & Mendivil, C. O. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.002 · Cited by 49 · see citing works

Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future

Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 49 · see citing works

ETC-1002: A future option for lipid disorders?

Nikolić, D., Mikhailidis, D. P., Davidson, M. H., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.099 · Cited by 47 · see citing works

Pharmacotherapies for lipid modification: beyond the statins

Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 44 · see citing works

LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase

Filippov, S. I., Pinkosky, S. L., & Newton, R. S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000091 · Cited by 44 · see citing works

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient ( LDLR +/− and LDLR −/− ) Yucatan Miniature Pigs

Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G., & Huff, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310676 · Cited by 46 · see citing works

Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43 · see citing works

ATP‐citrate lyase is an epigenetic regulator to promote obesity‐related kidney injury

Chen, Y., Deb, D. K., Fu, X., Yi, B., Liang, Y., Du, J., He, L., & Li, Y. C. (2019) · The FASEB Journal · doi:10.1096/fj.201900213r · Cited by 42 · see citing works

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 41 · see citing works

An update on pharmacotherapies in diabetic dyslipidemia

Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43 · see citing works

Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials

Dai, L., Zuo, Y., You, Q., Zeng, H., & Cao, S. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320930585 · Cited by 42 · see citing works

Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor

Zagelbaum, N. K., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000218 · Cited by 37 · see citing works

Bempedoic acid for the treatment of dyslipidemia

Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 36 · see citing works

A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia

Niman, S., Rana, K., Reid, J., Sheikh‐Ali, M., Lewis, T., Choksi, R. R., & Goldfaden, R. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00399-w · Cited by 36 · see citing works

Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model

Jadhav, S. B., Crass, R. L., Chapel, S. H., Kerschnitzki, M., Sasiela, W. J., Emery, M. G., Amore, B. M., Barrett, P. H. R., Watts, G. F., & Catapano, A. L. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab064 · Cited by 36 · see citing works

Recent advances in the pharmacological management of hypercholesterolaemia

Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36 · see citing works

Dyslipidemias in clinical practice

Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 36 · see citing works

Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition

Lau, F. D., & Giugliano, R. P. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2402 · Cited by 38 · see citing works

Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice

Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102401 · Cited by 35 · see citing works

Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential

Brandts, J., & Ray, K. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1778668 · Cited by 33 · see citing works

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

Bandyopadhyay, D., Ashish, K., Hajra, A., Qureshi, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/3179201 · Cited by 32 · see citing works

Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials

Wang, X., Luo, S., Gan, X., He, C., & Huang, R. (2019) · Kardiologia Polska · doi:10.5603/kp.a2019.0013 · Cited by 28 · see citing works

New and emerging lipid-modifying drugs to lower LDL cholesterol

Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 30 · see citing works

Intracellular Citrate/acetyl-CoA flux and endoplasmic reticulum acetylation: Connectivity is the answer

Fernandez-Fuente, G., Rigby, M. J., & Puglielli, L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101653 · Cited by 27 · see citing works

New Therapeutic Approaches for Familial Hypercholesterolemia

Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 25 · see citing works

Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering

Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 24 · see citing works

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside

Agarwala, A., Quispe, R., Goldberg, A. C., & Michos, E. D. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s251865 · Cited by 23 · see citing works

New and Emerging LDL Cholesterol–Lowering Drugs

Kosmas, C. E., & Frishman, W. H. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000063 · Cited by 23 · see citing works

The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials

Sayed, A., Shazly, O., Slipczuk, L., Krittanawong, C., Baloch, F., & Virani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07474-9 · Cited by 19 · see citing works

Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials

Zhao, X., Ma, X.-B., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00463-w · Cited by 19 · see citing works

Influence of lipid-lowering drugs on inflammation: what is yet to be done?

Ugovšek, S., Zupan, J., Likozar, A. R., & Šebeštjen, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/133936 · Cited by 19 · see citing works

CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?

Jia, X., & Virani, S. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012352 · Cited by 18 · see citing works

Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis

Mutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 17 · see citing works

Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper

Colivicchi, F., Fusco, S. A. D., Scicchitano, P., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., Aspromonte, N., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001108 · Cited by 18 · see citing works

Are some health benefits of palmitoleic acid supplementation due to its effects on 5′ adenosine monophosphate-activated protein kinase (AMPK)?

Morse, N. (2015) · Lipid Technology · doi:10.1002/lite.201500061 · Cited by 17 · see citing works

Novel treatment options for the management of heterozygous familial hypercholesterolemia

Polychronopoulos, G., & Τζιόμαλος, Κ. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1378096 · Cited by 16 · see citing works

LDL-Cholesterol-Lowering Therapy

Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 16 · see citing works

Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention

Albosta, M. S., Grant, J. K., & Michos, E. D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.1 · Cited by 16 · see citing works

Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart

Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15 · see citing works

Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance

Susekov, A. V., Король, Л. А., & Watts, G. F. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07139-x · Cited by 13 · see citing works

Ácido bempedoico. Mecanismo de acción y propiedades farmacocinéticas y farmacodinámicas

Masana, L., & Plana, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.012 · Cited by 15 · see citing works

Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid

Yarrarapu, S. N. S., Goyal, A., Venkata, V. S., Panchal, V. S., Sivasubramanian, B. P., Du, D. T., Jakulla, R. S., Pamulapati, H., Afaq, M. A., Owens, S., et al. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.03.006 · Cited by 14 · see citing works

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 13 · see citing works

Emerging therapeutic targets for NASH: key innovations at the preclinical level

Horn, P., & Newsome, P. (2020) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2020.1728742 · Cited by 10 · see citing works

Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy

Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12 · see citing works

Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH)

Agha, A. M., Jones, P. H., Ballantyne, C. M., Virani, S. S., & Nambi, V. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.07.002 · Cited by 11 · see citing works

Meta-analysis of the Safety and Efficacy of Bempedoic Acid

Khan, M. U., Khan, M. Z., Munir, M. B., Balla, S., & Khan, S. U. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.028 · Cited by 11 · see citing works

Novel therapeutic targets and agents for pediatric dyslipidemia

Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13 · see citing works

AMPK, a key molecule regulating aging-related myocardial ischemia-reperfusion injury

Yin, X., Guo, Z., & Song, C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09050-8 · Cited by 10 · see citing works

Statin myopathy

Maghsoodi, N., & Wierzbicki, A. S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000282 · Cited by 10 · see citing works

Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy

Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 9 · see citing works

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

Ballantyne, C. M., McKenney, J. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.043 · Cited by 117 · see citing works

Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy

Ballantyne, C. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.17499 · Cited by 4 · see citing works

ETC-1002 LOWERS LDL-C AND BENEFICIALLY MODULATES OTHER CARDIO-METABOLIC RISK FACTORS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH EITHER NORMAL OR ELEVATED TRIGLYCERIDES

Ballantyne, C. M., Davidson, M., MacDougall, D. E., Margulies, J. R., & DiCarlo, L. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(12)61626-x · Cited by 8 · see citing works

ETC-1002: A future option for lipid disorders?

Nikolić, D., Mikhailidis, D. P., Davidson, M. H., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.099 · Cited by 47 · see citing works

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170 · see citing works